Title: Early High-Dose Vitamin D3 for Critically Ill, Vitamin D Deficient Patients<br/>Author: Quincy Tran<br/><a href='http://umem.org/profiles/faculty/1281/'>[Click to email author]</a><hr/><p> <strong>Settings</strong>: multicenter, double-blind, phase 3 trial (apparently vitamin D worked in phase 2 trials).</p> <ul> <li> Patients: <ul> <li> 1059 patients were enrolled within 12 hours of ICU admission. The patients had to have risk factors warranted ICU admisions (pneumonia, sepsis, mechanical ventilation, shock, pancreatitis, etc.).</li> <li> Vitamin D deficiency was defined as plasma level < 20 ng/ml</li> </ul> </li> <li> Intervention: <ul> <li> 531 patients received a single oral dose of 540,000 IU of vitamin D3 within 2 hours after randomization</li> </ul> </li> <li> Comparison <ul> <li> 528 patients received placebo</li> </ul> </li> <li> Outcome <ul> <li> 90-day all-cause mortality</li> </ul> </li> </ul> <p> <strong>Study Results</strong>:</p> <ul> <li> Total SOFA score was similar in both groups (5.6 vs. 5.4). </li> <li> On day 3, mean plasma vitamin D was higher (47 ng/ml) in treatment group vs 11 ng/ml in placebo group</li> <li> 90-day all cause mortality was similar. Treatment group was 23.5% vs. 20.6% for placebo (95% CI, −2.1 to 7.9; P = 0.26).</li> <li> Vitamin D-related adverse events were similar in both groups.</li> </ul> <p> <strong>Discussion</strong>:</p> <ul> <li> This trial enrolled patients early in their critical illness compared to phase 2 trial which enrolled patients after 3 days in the ICU.</li> <li> This phase 3 trial also enrolled mostly medical-related illness, whereas 75% of patients in phase 2 had either surgical or neurology-related illnesses.</li> </ul> <p> <strong>Conclusion</strong>:</p> <p> Early administration of high dose vitamin D did not improve 90-day all cause mortality.</p> <p> </p> <fieldset><legend>References</legend>
<p> Early High-Dose Vitamin D3 for Critically Ill, Vitamin D-Deficient Patients.</p> <p> National Heart, Lung, and Blood Institute PETAL Clinical Trials Network, Ginde AA, Brower RG, Caterino JM, Finck L, Banner-Goodspeed VM, Grissom CK, Hayden D, Hough CL, Hyzy RC, Khan A, Levitt JE, Park PK, Ringwood N, Rivers EP, Self WH, Shapiro NI, Thompson BT, Yealy DM, Talmor D. N Engl J Med. 2019 Dec 26;381(26):2529-2540.</p> </fieldset>